Jenburkt Pharmaceuticals (524731) Q1 24/25 earnings summary

Executive summary

• Standalone unaudited financial results for the quarter ended 30th June 2024 were reviewed and approved by the Board on 26th July 2024.

• The company operates exclusively in the pharmaceuticals segment.

Financial highlights

• Revenue from operations for Q1 FY25 was ₹3,253.57 lakhs, up from ₹2,917.52 lakhs in Q1 FY24.

• Profit before tax for the quarter was ₹1,006.13 lakhs, compared to ₹743.01 lakhs in the same quarter last year.

• Profit after tax stood at ₹741.60 lakhs, up from ₹536.91 lakhs year-over-year.

• Total comprehensive income for the quarter was ₹896.68 lakhs, compared to ₹645.80 lakhs in Q1 FY24.

• Basic and diluted EPS for the quarter was ₹16.80, up from ₹12.17 in Q1 FY24.

Key financial ratios and metrics

• Gross margin improved as expenses grew at a slower rate than revenue year-over-year.

• Employee benefit expenses increased to ₹1,066.75 lakhs from ₹966.27 lakhs year-over-year.

• Finance costs rose to ₹11.48 lakhs from ₹7.38 lakhs in Q1 FY24.